JDRF International, in partnership with the Lupus Research Alliance and the National Multiple Sclerosis Society, is soliciting Letters of Intent (LOI) from investigators across autoimmune (and other relevant) fields to advance the understanding of autoimmunity and to obtain more specific insights into commonalities and differences of immune pathways that govern these pathogenic processes. The incomplete knowledge of immune networks, pathways, disease pathogenesis and heterogeneity across multiple autoimmune diseases remains a challenge towards achieving optimal therapies to effectively treat all subjects in a given indication.
The purpose of this call is to invite innovative ideas that address needs across multiple autoimmune diseases in novel ways that may allow us to make faster progress together. Applications must address one or more of the following autoimmune diseases: Type 1 Diabetes (T1D), Systemic Lupus Erythematosus (SLE) and Multiple Sclerosis (MS).
Funding & Duration
Strategic Research Agreements (SRA): proposed project budgets should not exceed USD $750,000 (approx. AUD $1.1M) for up to three years.
Pilot & Feasibility (PNF) projects: should be limited to a total proposed budget of USD $200,000 (approx. AUD $286,000) for up to two years.
View the Program Guidelines (PDF) for eligibility details.
Submission Requirements & Due Dates
- 9 September 2019 – Letter of Intent (LOI)
- 26 November 2019 – full applications submitted for internal review.
- Please email email@example.com if you are considering applying for this scheme.
- See also: Submitting an Application to Research Services for Review